GW856553

Phase 2Small molecule

GSK

GW856553 is one of 110 small molecule programs targeting Peripheral Nerve Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Nerve InjuryActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Myocardial InfarctionActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Peripheral Nerve InjuryPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Myocardial InfarctionPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Cimzia

UCB

Preclinical

30 3

Simponi

Johnson & Johnson

Preclinical

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

GW856553

GSK

Phase 2

2 7

Arcoxia

Novartis

Preclinical

4 8

Celexa

AbbVie

Preclinical

1 9

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 2·NCT00642148·306 enrolled

A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)

Completed· GSK logo

GSK·Phase 2·NCT00392587·30 enrolled

Rheumatoid Arthritis2 trials

A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

Completed· GSK logo

GSK·Phase 2·NCT00393146·57 enrolled

Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Completed· GSK logo

GSK·Phase 2·NCT00256919·51 enrolled

ART1 trial

A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

Completed· GSK logo

GSK·Phase 1·NCT00517543·36 enrolled

Endothelial Function1 trial

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Completed· GSK logo

GSK·Phase 2·NCT00474864·66 enrolled

Myocardial Infarction1 trial

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

Completed· GSK logo

GSK·Phase 2·NCT00910962·526 enrolled

4 more indications

Excretion1 trial

To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males

Completed· GSK logo

GSK·Phase 1·NCT00599612·6 enrolled

Concentration1 trial

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

Completed· GSK logo

GSK·Phase 1·NCT00549653·44 enrolled

Peripheral Nerve Injury1 trial

Study in Neuropathic Pain Patients With Peripheral Nerve Injury

Completed· GSK logo

GSK·Phase 2·NCT00969059·168 enrolled

Major Depression1 trial

Clinical Study to Test a New Drug to Treat Major Depression

Completed· GSK logo

GSK·Phase 2·NCT00976560·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for GW856553. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GW856553 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GW856553. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GW856553

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Rheumatoid Arthritis2 trials

ART1 trial

Endothelial Function1 trial

Myocardial Infarction1 trial

Excretion1 trial

Concentration1 trial

Peripheral Nerve Injury1 trial

Major Depression1 trial

References

Drug Info

Quick Facts

Related News